New York City, October 31, 2025
Rosen Law Firm has launched an investigation into Tvardi Therapeutics, Inc. over potential securities class action claims regarding alleged misleading information that may have impacted investor decisions. This comes after a significant drop in share price following the company’s announcement about its Phase 2 REVERT clinical trial for idiopathic pulmonary fibrosis, which did not meet primary endpoints. Investors are encouraged to reach out to the firm for participation in the class action lawsuit.
New York, NY – On the brink of significant implications for investors, Rosen Law Firm has initiated an investigation into Tvardi Therapeutics, Inc. (NASDAQ: TVRD). The investigation focuses on potential securities class action claims tied to allegations that the company may have disseminated materially misleading business information to its shareholders.
Background of the Investigation
The investigation follows Tvardi Therapeutics’ announcement on October 13, 2025, regarding preliminary findings from its Phase 2 REVERT clinical trial for idiopathic pulmonary fibrosis (IPF). The company’s report indicated that the trial did not meet its primary endpoints, resulting in a staggering 83.9% drop in share price on the same day. This steep decline has raised serious concerns about the transparency and accuracy of the company’s prior disclosures pertaining to the trial’s development and results.
Investor Implications
The decline in Tvardi Therapeutics’ stock price has left many investors grappling with substantial financial losses, stemming from the alleged misrepresentation of crucial business information. In response, Rosen Law Firm is preparing a class action lawsuit, aimed at seeking recovery for the affected shareholders. Those who purchased Tvardi Therapeutics securities and wish to become part of this prospective class action are encouraged to contact the Rosen Law Firm for further guidance.
Rosen Law Firm Overview
Rosen Law Firm has a commendable reputation in the realm of investor rights, recognized as one of the leading law firms to pursue securities class actions. Consistently ranked among the top four law firms since 2013 based on successful securities class actions, the firm exemplifies a strong commitment to protecting shareholders’ interests. In 2019 alone, Rosen Law Firm successfully secured over $438 million for investors, demonstrating their effectiveness in navigating complex litigation.
Contact Information
Shareholders interested in joining the prospective class action may reach out to the firm using the following details:
– Laurence Rosen, Esq.
– Phillip Kim, Esq.
– The Rosen Law Firm, P.A.
– 275 Madison Avenue, 40th Floor
– New York, NY 10016
– Tel: (212) 686-1060
– Email: [email protected]
Key Features
| Feature | Details |
|---|---|
| Investigation Focus | Potential securities class action claims on behalf of shareholders of Tvardi Therapeutics, Inc. (NASDAQ: TVRD) due to alleged misleading business information. |
| Triggering Event | Announcement on October 13, 2025, that the Phase 2 REVERT clinical trial for idiopathic pulmonary fibrosis did not meet its endpoints, leading to a significant stock price decline. |
| Investor Action | Shareholders who purchased Tvardi Therapeutics securities and wish to join the prospective class action are encouraged to contact Rosen Law Firm for more information. |
| Law Firm’s Track Record | Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, the firm secured over $438 million for investors. |
FAQ
What is the nature of the investigation by Rosen Law Firm?
Rosen Law Firm is investigating potential securities class action claims on behalf of shareholders of Tvardi Therapeutics, Inc. (NASDAQ: TVRD) due to allegations that the company may have issued materially misleading business information to the investing public.
What event triggered the investigation?
The investigation was triggered by Tvardi Therapeutics’ announcement on October 13, 2025, that its Phase 2 REVERT clinical trial for idiopathic pulmonary fibrosis did not meet its endpoints, leading to a significant decline in the company’s stock price.
How can investors join the prospective class action?
Investors who purchased Tvardi Therapeutics securities and wish to join the prospective class action can contact Rosen Law Firm for more information. Contact details are provided above.
What is the track record of Rosen Law Firm in securities class actions?
Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, the firm secured over $438 million for investors.
Now Happening on X
- @NewsFromBW (October 24, 2025): Rosen Law Firm is encouraging Tvardi Therapeutics, Inc. investors to inquire about a securities class action investigation related to TVRD stock. View on X
- @NewsFromBW (October 31, 2025): Rosen Law Firm urges Tvardi Therapeutics, Inc. investors to contact them regarding a potential securities class action investigation for TRVD shareholders. View on X
- @BLaw (October 28, 2025): A litigation investor is suing a New York law firm for nearly $5.3 million, alleging failure to deliver results in mass tort cases and tax credit claims. View on X
- @NewsFromBW (October 30, 2025): Rosen Law Firm is urging Savara Inc. (SVRA) stockholders to contact them before the deadline for information on their rights in a potential securities class action. View on X
- @NewsFromBW (October 31, 2025): Rosen Law Firm encourages Larimar Therapeutics, Inc. investors to inquire about a securities class action investigation involving LRMR stock. View on X
- @NewsFromBW (October 30, 2025): Rosen Law Firm is reaching out to Soleno Therapeutics, Inc. investors regarding a securities class action investigation for SLNO. View on X
- @NewsFromBW (October 26, 2025): Rosen Law Firm urges Dow Inc. (DOW) stockholders with losses to contact the firm for details on their rights in a securities class action. View on X
- @NewsFromBW (October 28, 2025): Rosen Law Firm is encouraging DexCom, Inc. (DXCM) stockholders with significant losses to reach out for information on their rights in a securities matter. View on X
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE NEW YORK WRITER
The NEW YORK STAFF WRITER represents the experienced team at HERENewYork.com, your go-to source for actionable local news and information in New York, the five boroughs, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as New York Fashion Week, Macy's Thanksgiving Day Parade, and Tribeca Film Festival. Our coverage extends to key organizations like the Greater New York Chamber of Commerce and United Way of New York, plus leading businesses in finance and media that power the local economy such as JPMorgan Chase, Goldman Sachs, and Bloomberg. As part of the broader HERE network, including HEREBuffalo.com, we provide comprehensive, credible insights into New York's dynamic landscape.
